Hims & Hers Health Inc. (NYSE:HIMS) saw its stock climb 5.8% in premarket trading Tuesday after revealing plans to acquire ZAVA, a leading European telehealth company. The all-cash transaction, expected to close in the second half of 2025, will enable the U.S.-based digital health firm to expand into Germany, France, Ireland, and strengthen its footprint in the U.K.
The acquisition represents a major milestone in Hims & Hers’ international strategy as it aims to position itself as a global leader in digital healthcare. With ZAVA’s 1.3 million active users, Hims & Hers is poised to increase its total customer base by over 50%, building on its existing 2.4 million users in the United States.
ZAVA’s platform handled nearly 2.3 million online consultations in 2024 across the U.K., Germany, France, and Ireland – showcasing strong market knowledge and operational capacity. Hims & Hers intends to launch branded operations in these countries, combining ZAVA’s established clinical systems with its own technology and consumer-focused care model.
“The demand for simpler, more personalized healthcare is universal,” said Andrew Dudum, founder and CEO of Hims & Hers. “By leveraging ZAVA’s established European presence, cutting-edge technology, and deep customer understanding, we’re poised to fundamentally transform access to care for millions across Europe.”
ZAVA’s CEO and co-founder David Meinertz echoed that sentiment, saying: “By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe.”
Post-acquisition, Hims & Hers will offer its services in areas such as dermatology, weight loss, sexual health, and mental health – with localized language support through providers in the U.K., France, and Germany. The company stated that further details would be shared in the coming months and that the transaction is expected to be accretive by 2026.
“We’re excited to take this moment to really accelerate both the European expansion, but also use this platform as an accelerant as we move into more markets,” Dudum said in an interview with CNBC.
With direct-to-consumer healthcare gaining global momentum, this expansion signals a new chapter for Hims & Hers and a broader evolution in international telemedicine. Investors appeared to back the move, as shares gained 5.8% in early trading, reflecting growing confidence in the company’s cross-border growth plans.